Skip to main content
SpringerLink
Log in

UEGW 2014, Vienne, 20–22 octobre 2014 maladies inflammatoires chroniques de l’intestin

Inflammatory bowel diseases

  • Comptes-Rendus de Congrès / Congresses, Conferences
  • Published:
Acta Endoscopica

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Hanauer S, Rutgeerts P, Xu J, Rubin DT, Smyth M, Abhyancar B. Long term efficacy of vedolizumab therapy for Crohn’s disease. United European Gastroenterol J 2014;2(5S):A66.

    Google Scholar 

  2. Feagan B, Kaser A, Smyth M, Panaccione R, Sankoh S, Abhyankar B. Long term efficacy of vedolizumab therapy for ulcerative colitis. United European Gastroenterol J 2014;2(5S):A66.

    Google Scholar 

  3. Sands BE, Dubinski C, Vermeire S, Sankoh S, Rosario M, Milch C. Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn’s disease. United European Gastroenterol J 2014;2(5S):A67.

    Google Scholar 

  4. Colombel JF, Siegel CA, Abhyankar B, Loftus EV, Lewis JD, Sankoh S, et al. Safety of vedolizumab alone or with concomitant corticosteroids and/or immunosuppressants in patients with ulcerative colitis or crohn’s disease. United European Gastroenterol J 2014;2(5S):A82.

    Google Scholar 

  5. Rutgeerts P, Reinisch W, Feagan B, Sandborn W, Tarabar D, Hebzda Z, et al. How long should golimumab treatment be continued in patients with ulcerative colitis who do not respond to initial induction therapy? United European Gastroenterol J 2014;2(5S):A67.

    Google Scholar 

  6. Monteleone G, Neurath MF, Ardizzone S, Sabatino AD, Fantini MC, Castiglione F et al. Mongersen, an oral smad7 antisense oligonucleotide, in active crohn’s disease. United European Gastroenterol J 2014;2(5S):A65.

    Google Scholar 

  7. Harris MS, Hartman D, Spence S, Kenndy S, Ptak T, Pruitt R, et al. AVX-470, an orally delivered anti-TNF antibody for treatment of acute ulcerative colitis: results of a first-in-human trial. United European Gastroenterol J 2014;2(5S):A65.

    Google Scholar 

  8. Bouhnik Y, Laharie D, Stefanescu C, Hebuterne X, Abitbol V, Nachury M, et al. Efficacy of adalimumab in patients with crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort stydy. United European Gastroenterol J 2014;2(5S):A41.

    Google Scholar 

  9. Szepes Z, Balint A, Torocsik D, Palatka K, Szucs M, Nagy F, et al. Effectiveness and safety of endoscopic balloon dilatation for strictures in crohn’s disease–A multicenter study. United European Gastroenterol J 2014;2(5S):A11.

    Google Scholar 

  10. Hirai F, Matsumoto T, Matsui T. Efficacy of endoscopic balloon dilatation for small bowel strictures in patients with crohn’s disease: a nationwide, multicenter, open-label, prospective cohort study. United European Gastroenterol J 2014;2(5S):A12.

    Google Scholar 

  11. Bortlik M, Duricova D, Lukas M, Machkova N, Hruba V, Romanko I, et al. Endoscopic balloon dilatation of strictures in crohn’s disease patients: safe and effective alternative to repeated surgery. United European Gastroenterol J 2014;2(5S):A385.

    Google Scholar 

  12. Digby J, Steele RJ, Strachan JA, Mowat C. Stool tests can potentially rule out significant bowel disease in symptomatic patients in primary care. United European Gastroenterol J 2014;2(5S):A47.

    Google Scholar 

  13. Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L et al. Risk of dysplasia and cancer complicating colonic strictures in inflammatory bowel disease: a GETAID study. United European Gastroenterol J 2014;(5S):A69.

    Google Scholar 

  14. Boschetti G, Laidet M, Moussata D, Stefanescu C, Roblin X, Phelip G, et al. Levels of fecal calprotectin are associated with the severity of postoperative endoscopic recurrence in patients with crohn’s disease. United European Gastroenterol J 2014;2(5S):A44.

    Google Scholar 

  15. Barriero de Acosta M, Vallejo-Senra N, De la Iglesia-Garcia D, Uribarri-Gonzalez L, Baston-Rey I, Ferreiro-Iglesias R, et al. A prospective observational cohort study to evaluate mucosal healing in ulcerative colitis: have Mayo 1 and Mayo 0 scores really the same prognostic value? United European Gastroenterol J 2014;2(5S):A89.

    Google Scholar 

  16. Moussata D, Boschetti G, Chauvenet M, Stroeymeyt K, Boyer S, Nancey S, et al. Serrated polyps in patients with inflammatory bowel disease (IBD): Endoscopic characteristics differ from serrated polyps in no-IBD population. United European Gastroenterol J 2014;2(5S):A69.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital privé La Casamance, Aubagne, France

    D. Bernardini

  2. Générale de Santé, Hôpital privé La Louvière, Lille, France

    P. Bulois

  3. 20 rue du Ballon, F-59000, Lille, France

    P. Bulois

Authors
  1. D. Bernardini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Bulois
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Bulois.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernardini, D., Bulois, P. UEGW 2014, Vienne, 20–22 octobre 2014 maladies inflammatoires chroniques de l’intestin. Acta Endosc 45, 75–78 (2015). https://doi.org/10.1007/s10190-014-0427-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10190-014-0427-4

Search

Navigation